首页 > 最新文献

中华眼科杂志最新文献

英文 中文
[Advances in clinical diagnosis and treatment of microsporidial keratitis]. [小孢子虫角膜炎临床诊断和治疗进展]。
Q3 Medicine Pub Date : 2024-10-11 DOI: 10.3760/cma.j.issn.0412-4081-20240329-00149
F Guo, Q F Liang

Microsporidia, a unicellular eukaryotic microorganism, poses a risk of infecting the eyes, precipitating microsporidia keratitis (MK). This condition typically manifests in two forms: microsporidian keratoconjunctivitis (MKC) or stromal keratitis (MSK). While MKC often resolves spontaneously, it can progress to MSK, a vision-threatening condition that, in severe instances, may lead to corneal perforation. Epidemiological studies reveal that MK is prevalent in Southeast Asia, particularly during the rainy season. Diagnosis encompasses a range of methods, including corneal scraping for microbiological analysis, PCR testing, and advanced imaging techniques such as AS-OCT and IVCM. Therapeutic approaches vary, with MKC typically managed through local and systemic drug therapy, while MSK may necessitate more aggressive interventions, including corneal transplantation. In China, MK case reports are scarce, and physicians still grapple with a lack of comprehensive understanding regarding its clinical presentation, diagnostic strategies, and treatment options. This deficit can lead to missed or misdiagnoses, as well as overtreatment. Consequently, this review endeavors to comprehensively outline the epidemiology, etiology, clinical features, diagnostic modalities, and therapeutic interventions for MK, thereby offering valuable insights and guidance for clinical practice.

小孢子虫是一种单细胞真核微生物,有感染眼睛的风险,会引发小孢子虫性角膜炎(MK)。这种疾病通常有两种表现形式:微孢子虫性角结膜炎(MKC)或基质性角膜炎(MSK)。小孢子虫性角结膜炎通常可自行缓解,但也可能发展为基质性角膜炎,这是一种威胁视力的疾病,严重时可能导致角膜穿孔。流行病学研究表明,MKC 在东南亚很普遍,尤其是在雨季。诊断方法多种多样,包括角膜刮片微生物分析、PCR 检测以及 AS-OCT 和 IVCM 等先进的成像技术。治疗方法各不相同,MKC 通常通过局部和全身药物治疗来控制,而 MSK 可能需要更积极的干预措施,包括角膜移植。在中国,MK 病例报告很少,医生对其临床表现、诊断策略和治疗方案仍缺乏全面了解。这种不足可能导致漏诊或误诊,以及过度治疗。因此,本综述试图全面概述 MK 的流行病学、病因学、临床特征、诊断方式和治疗干预措施,从而为临床实践提供有价值的见解和指导。
{"title":"[Advances in clinical diagnosis and treatment of microsporidial keratitis].","authors":"F Guo, Q F Liang","doi":"10.3760/cma.j.issn.0412-4081-20240329-00149","DOIUrl":"https://doi.org/10.3760/cma.j.issn.0412-4081-20240329-00149","url":null,"abstract":"<p><p>Microsporidia, a unicellular eukaryotic microorganism, poses a risk of infecting the eyes, precipitating microsporidia keratitis (MK). This condition typically manifests in two forms: microsporidian keratoconjunctivitis (MKC) or stromal keratitis (MSK). While MKC often resolves spontaneously, it can progress to MSK, a vision-threatening condition that, in severe instances, may lead to corneal perforation. Epidemiological studies reveal that MK is prevalent in Southeast Asia, particularly during the rainy season. Diagnosis encompasses a range of methods, including corneal scraping for microbiological analysis, PCR testing, and advanced imaging techniques such as AS-OCT and IVCM. Therapeutic approaches vary, with MKC typically managed through local and systemic drug therapy, while MSK may necessitate more aggressive interventions, including corneal transplantation. In China, MK case reports are scarce, and physicians still grapple with a lack of comprehensive understanding regarding its clinical presentation, diagnostic strategies, and treatment options. This deficit can lead to missed or misdiagnoses, as well as overtreatment. Consequently, this review endeavors to comprehensively outline the epidemiology, etiology, clinical features, diagnostic modalities, and therapeutic interventions for MK, thereby offering valuable insights and guidance for clinical practice.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 10","pages":"854-859"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Three-year results of XEN gel stent implantation in the treatment of glaucoma]. [XEN凝胶支架植入治疗青光眼的三年结果]。
Q3 Medicine Pub Date : 2024-10-11 DOI: 10.3760/cma.j.cn112142-20240513-00225
Y Q Chen, Y H Yao, Q Ye, X H Wang, Y Lin, Y H Zhu

Objective: To evaluate the long-term efficacy and safety of XEN gel stent implantation in patients with refractory glaucoma. Methods: A retrospective case series study was conducted. Clinical data were collected from patients who received medical treatment at the First Affiliated Hospital of Fujian Medical University between January 2020 and September 2020 and underwent XEN gel stent implantation by the same surgeon. Preoperative and postoperative clinical parameters, including the intraocular pressure (IOP), number of ocular hypotensive medications, best-corrected visual acuity, surgical success rates, status of filtering blebs, and complications, were recorded at 1 day, 1 week, 1, 2, 3, 6, 12, 18, 24, and 36 months after surgery. Statistical analyses were performed using the analysis of variance (ANOVA), the least significant difference (LSD) method, and the Fisher's precision probability test. Results: A total of 8 patients (8 eyes) with glaucoma meeting the criteria were included, consisting of 6 males (6 eyes) and 2 females (2 eyes). The preoperative IOP reached (30.88±12.17) mmHg (1 mmHg=0.133 kPa), and the IOP at all postoperative follow-up time points was significantly lower than the preoperative value (P<0.05). At 3 years after surgery, the IOP was (14.38±1.60) mmHg, with a reduction of 53.43% [(16.50±12.07) mmHg]. Only 2 patients required monotherapy for IOP control, and there was no significant decline in best-corrected visual acuity in 7 patients. The surgical outcome at 3 years postoperatively was a complete success in 6 patients, a qualified success in 1 patient, and a failure in 1 patient. The filtering blebs were generally flat and diffuse, with only mild to moderate vascularization. One patient presented elevated IOP at 3 months, and after a subsequent revision of the XEN gel stent, the IOP became stable with the administration of travoprost eye drops. Conclusion: The XEN gel stent implantation proved to effectively reduce the IOP in glaucoma patients, with a high degree of safety demonstrated up to 3-year long-term follow-up.

目的:评估 XEN 凝胶支架植入术对难治性青光眼患者的长期疗效和安全性:评估 XEN 凝胶支架植入术对难治性青光眼患者的长期疗效和安全性。方法:进行回顾性病例系列研究:进行回顾性病例系列研究。收集2020年1月至2020年9月期间在福建医科大学附属第一医院接受治疗并由同一外科医生进行XEN凝胶支架植入术的患者的临床数据。记录术前和术后的临床参数,包括眼压(IOP)、降眼压药物次数、最佳矫正视力、手术成功率、滤过性出血状况和并发症,时间分别为术后1天、1周、1、2、3、6、12、18、24和36个月。统计分析采用方差分析(ANOVA)、最小显著差异法(LSD)和费雪精确概率检验。结果符合标准的青光眼患者共有 8 人(8 眼),其中男性 6 人(6 眼),女性 2 人(2 眼)。术前眼压为(30.88±12.17)mmHg(1 mmHg=0.133 kPa),术后所有随访时间点的眼压均显著低于术前值(PConclusion:事实证明,XEN凝胶支架植入术能有效降低青光眼患者的眼压,长期随访3年,安全性很高。
{"title":"[Three-year results of XEN gel stent implantation in the treatment of glaucoma].","authors":"Y Q Chen, Y H Yao, Q Ye, X H Wang, Y Lin, Y H Zhu","doi":"10.3760/cma.j.cn112142-20240513-00225","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20240513-00225","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the long-term efficacy and safety of XEN gel stent implantation in patients with refractory glaucoma. <b>Methods:</b> A retrospective case series study was conducted. Clinical data were collected from patients who received medical treatment at the First Affiliated Hospital of Fujian Medical University between January 2020 and September 2020 and underwent XEN gel stent implantation by the same surgeon. Preoperative and postoperative clinical parameters, including the intraocular pressure (IOP), number of ocular hypotensive medications, best-corrected visual acuity, surgical success rates, status of filtering blebs, and complications, were recorded at 1 day, 1 week, 1, 2, 3, 6, 12, 18, 24, and 36 months after surgery. Statistical analyses were performed using the analysis of variance (ANOVA), the least significant difference (LSD) method, and the Fisher's precision probability test. <b>Results:</b> A total of 8 patients (8 eyes) with glaucoma meeting the criteria were included, consisting of 6 males (6 eyes) and 2 females (2 eyes). The preoperative IOP reached (30.88±12.17) mmHg (1 mmHg=0.133 kPa), and the IOP at all postoperative follow-up time points was significantly lower than the preoperative value (<i>P</i><0.05). At 3 years after surgery, the IOP was (14.38±1.60) mmHg, with a reduction of 53.43% [(16.50±12.07) mmHg]. Only 2 patients required monotherapy for IOP control, and there was no significant decline in best-corrected visual acuity in 7 patients. The surgical outcome at 3 years postoperatively was a complete success in 6 patients, a qualified success in 1 patient, and a failure in 1 patient. The filtering blebs were generally flat and diffuse, with only mild to moderate vascularization. One patient presented elevated IOP at 3 months, and after a subsequent revision of the XEN gel stent, the IOP became stable with the administration of travoprost eye drops. <b>Conclusion:</b> The XEN gel stent implantation proved to effectively reduce the IOP in glaucoma patients, with a high degree of safety demonstrated up to 3-year long-term follow-up.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 10","pages":"845-851"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparison and analysis of ophthalmic resources and service ability in Shanxi Province in 2014 and 2021]. [2014年与2021年山西省眼科资源与服务能力对比分析]。
Q3 Medicine Pub Date : 2024-10-11 DOI: 10.3760/cma.j.cn112142-20240506-00205
J P Xue, L Cheng, J Shen, S R Chen, C Z Yang

Objective: To compare and analyze the ophthalmic resources and service ability in Shanxi Province in 2014 and 2021, and to provide reference for the development planning of ophthalmology and eye care. Methods: In this cross-sectional study, a questionnaire survey was conducted among all ophthalmic institutions registered in the health administrative department in 11 cities of Shanxi Province by the end of 2014 and 2021 by using the National Ophthalmology Competency Resource Questionnaire (compiled by the Medical Administration and Hospital Authority of the National Health and Wellness Commission). The basic situations of ophthalmic institutions in 2014 and 2021, as well as the human resources, ophthalmic equipment configuration, technology and medical service capabilities, were recorded and compared. The chi-square test was used for statistical analysis. Results: A total of 270 questionnaires for 2014 were collected from 270 ophthalmic institutions, and 292 questionnaires for 2021 from 292 ophthalmic institutions. The institution categories in 2014 (197 general hospitals, 31 eye hospitals and 42 others) were statistically different from those in 2021 (182 general hospitals, 45 eye hospitals and 65 others) (P<0.05). The proportion of doctors with senior titles in ophthalmic institutions increased from 25.5% (346/1 358) in 2014 to 41.7% (580/1 391) in 2021, the proportion of senior technicians increased from 9.4% (14/148) to 25.3% (110/435), the proportion of doctors with junior titles decreased from 42.1% (572/1 358) to 26.5% (369/1 391), and the proportion of junior technicians decreased from 45.3% (67/148) to 39.1% (170/435). There was a significant difference in the distribution of professional titles between doctors and technicians in ophthalmic institutions (P<0.05). The number of doctors (130 to 28), nurses (152 to 50), technicians (33 to 11) and full-time optometrists (44 to 12) in the first-class ophthalmic institutions decreased, the increase of equipment with the ophthalmic A-ultrasound scan system, fundus camera and coherent optical tomography system (35.1%, 28.9% and 25.4%; P<0.05) ranked the top three, and the increase of performing the phacoemulsification procedure, intraocular lens implantation, intravitreal injection and iris surgery (30.2%, 24.7% and 20.7%; P<0.05) ranked the top three in 2021 as compared to 2014. Conclusions: The resources and service ability of ophthalmology in Shanxi Province developed in 2021 in comparison with 2014. However, there were some problems, such as changes in the type and structure of eye institutions, unreasonable proportions of professional titles, insufficient human resources in primary ophthalmic institutions, and slow improvement in the allocation of ophthalmology equipment and technical capabilities.

目的对比分析山西省 2014 年和 2021 年眼科资源和服务能力,为眼科和眼保健发展规划提供参考。研究方法本横断面研究采用《全国眼科能力资源调查表》(国家卫生健康委员会医政医管局编制),对山西省11个市2014年底和2021年在卫生行政部门注册的所有眼科机构进行问卷调查。记录并比较了 2014 年和 2021 年眼科机构的基本情况,以及人力资源、眼科设备配置、技术水平和医疗服务能力。统计分析采用卡方检验。结果共收集到 270 家眼科机构的 2014 年问卷 270 份,292 家眼科机构的 2021 年问卷 292 份。2014年的机构类别(197家综合医院、31家眼科医院和42家其他医院)与2021年的机构类别(182家综合医院、45家眼科医院和65家其他医院)在统计学上存在差异(PPPPC结论:与 2014 年相比,2021 年山西省眼科资源和服务能力有所发展。但也存在一些问题,如眼科机构类型和结构发生变化、职称比例不合理、基层眼科机构人力资源不足、眼科设备配置和技术能力提升缓慢等。
{"title":"[Comparison and analysis of ophthalmic resources and service ability in Shanxi Province in 2014 and 2021].","authors":"J P Xue, L Cheng, J Shen, S R Chen, C Z Yang","doi":"10.3760/cma.j.cn112142-20240506-00205","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20240506-00205","url":null,"abstract":"<p><p><b>Objective:</b> To compare and analyze the ophthalmic resources and service ability in Shanxi Province in 2014 and 2021, and to provide reference for the development planning of ophthalmology and eye care. <b>Methods:</b> In this cross-sectional study, a questionnaire survey was conducted among all ophthalmic institutions registered in the health administrative department in 11 cities of Shanxi Province by the end of 2014 and 2021 by using the National Ophthalmology Competency Resource Questionnaire (compiled by the Medical Administration and Hospital Authority of the National Health and Wellness Commission). The basic situations of ophthalmic institutions in 2014 and 2021, as well as the human resources, ophthalmic equipment configuration, technology and medical service capabilities, were recorded and compared. The chi-square test was used for statistical analysis. <b>Results:</b> A total of 270 questionnaires for 2014 were collected from 270 ophthalmic institutions, and 292 questionnaires for 2021 from 292 ophthalmic institutions. The institution categories in 2014 (197 general hospitals, 31 eye hospitals and 42 others) were statistically different from those in 2021 (182 general hospitals, 45 eye hospitals and 65 others) (<i>P</i><0.05). The proportion of doctors with senior titles in ophthalmic institutions increased from 25.5% (346/1 358) in 2014 to 41.7% (580/1 391) in 2021, the proportion of senior technicians increased from 9.4% (14/148) to 25.3% (110/435), the proportion of doctors with junior titles decreased from 42.1% (572/1 358) to 26.5% (369/1 391), and the proportion of junior technicians decreased from 45.3% (67/148) to 39.1% (170/435). There was a significant difference in the distribution of professional titles between doctors and technicians in ophthalmic institutions (<i>P</i><0.05). The number of doctors (130 to 28), nurses (152 to 50), technicians (33 to 11) and full-time optometrists (44 to 12) in the first-class ophthalmic institutions decreased, the increase of equipment with the ophthalmic A-ultrasound scan system, fundus camera and coherent optical tomography system (35.1%, 28.9% and 25.4%; <i>P</i><0.05) ranked the top three, and the increase of performing the phacoemulsification procedure, intraocular lens implantation, intravitreal injection and iris surgery (30.2%, 24.7% and 20.7%; <i>P</i><0.05) ranked the top three in 2021 as compared to 2014. <b>Conclusions:</b> The resources and service ability of ophthalmology in Shanxi Province developed in 2021 in comparison with 2014. However, there were some problems, such as changes in the type and structure of eye institutions, unreasonable proportions of professional titles, insufficient human resources in primary ophthalmic institutions, and slow improvement in the allocation of ophthalmology equipment and technical capabilities.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 10","pages":"838-844"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress of retinal neuroprotective drugs for glaucoma]. [青光眼视网膜神经保护药物的研究进展]。
Q3 Medicine Pub Date : 2024-10-11 DOI: 10.3760/cma.j.cn112142-20240502-00203
X Y Liu, X H Sun

Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.

青光眼是一种神经退行性疾病,其特点是视网膜神经节细胞逐渐丧失,导致不可逆转的视野缺损、低视力和完全失明。尽管病理性眼压升高是青光眼的主要风险因素,但当务之急是开发出除降低眼压外,还能预防和阻止视网膜神经节细胞损伤和凋亡的疗法。在大多数临床病例中,药物治疗是青光眼的主要治疗方法。本文根据国内外最新研究成果,总结分析了在临床或临床前试验中对视神经有直接保护作用的药物,为青光眼的临床治疗提供参考信息。
{"title":"[Research progress of retinal neuroprotective drugs for glaucoma].","authors":"X Y Liu, X H Sun","doi":"10.3760/cma.j.cn112142-20240502-00203","DOIUrl":"10.3760/cma.j.cn112142-20240502-00203","url":null,"abstract":"<p><p>Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 10","pages":"860-869"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Role and mechanism of autonomic nervous system regulation in primary glaucoma]. [原发性青光眼中自律神经系统调节的作用和机制]。
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.cn112142-20231103-00203
L Zhu, X L Shen, A Z Li, J T Wang

The regulation of blood flow in the human eye, aqueous humor production, and the outflow channels of aqueous humor are all controlled by the autonomic nervous system (ANS), encompassing both sympathetic and parasympathetic nerves. Patients with primary glaucoma often exhibit autonomic nervous system dysfunctions, which may exacerbate visual impairment. The homeostasis of the autonomic nervous system is influenced by circadian rhythms, physical exercise, emotional states, medications, and other factors. Previous studies have indicated that activities such as aerobic exercise, yoga breathing, and meditation can promote the restoration of autonomic nervous system balance, thereby reducing intraocular pressure. However, further evidence is required to substantiate the efficacy of ANS activity regulation as an effective adjunct therapy for primary glaucoma. This review examines the role and mechanisms of autonomic nervous system regulation in the context of primary glaucoma.

人眼血流的调节、房水的产生以及房水的流出通道都是由自律神经系统(ANS)控制的,其中包括交感神经和副交感神经。原发性青光眼患者通常会表现出自律神经系统功能障碍,这可能会加重视力损伤。自律神经系统的平衡受到昼夜节律、体育锻炼、情绪状态、药物和其他因素的影响。以往的研究表明,有氧运动、瑜伽呼吸和冥想等活动可以促进自律神经系统恢复平衡,从而降低眼压。然而,要证实自律神经系统活动调节作为原发性青光眼有效辅助疗法的疗效,还需要进一步的证据。本综述探讨了自律神经系统调节在原发性青光眼中的作用和机制。
{"title":"[Role and mechanism of autonomic nervous system regulation in primary glaucoma].","authors":"L Zhu, X L Shen, A Z Li, J T Wang","doi":"10.3760/cma.j.cn112142-20231103-00203","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20231103-00203","url":null,"abstract":"<p><p>The regulation of blood flow in the human eye, aqueous humor production, and the outflow channels of aqueous humor are all controlled by the autonomic nervous system (ANS), encompassing both sympathetic and parasympathetic nerves. Patients with primary glaucoma often exhibit autonomic nervous system dysfunctions, which may exacerbate visual impairment. The homeostasis of the autonomic nervous system is influenced by circadian rhythms, physical exercise, emotional states, medications, and other factors. Previous studies have indicated that activities such as aerobic exercise, yoga breathing, and meditation can promote the restoration of autonomic nervous system balance, thereby reducing intraocular pressure. However, further evidence is required to substantiate the efficacy of ANS activity regulation as an effective adjunct therapy for primary glaucoma. This review examines the role and mechanisms of autonomic nervous system regulation in the context of primary glaucoma.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"780-786"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Metachronous bilateral retinoblastoma: a case report]. [双侧同步性视网膜母细胞瘤:病例报告]
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.issn.cn112142-20240129-00053
Reyizha Mengjiang, J Yang, X Y Wen, J Y Fan

The patient is a 2-year-old male. The family consulted the Department of Ophthalmology, Shanghai Ninth People's Hospital, after noticing a white reflection in the pupil area of the child's right eye for 6 days. Following a thorough ocular and systemic examination, the patient was diagnosed with retinoblastoma (Group E, cT2bN0M0) of the right eye. The right eye was enucleated and classified as pathological stage pT3cN0M0. Postoperatively, systemic intravenous chemotherapy with the VEC regimen was administered. Genetic testing revealed a germline mutation in the RB1 gene: c.874 (exon9) delT (p.Tyr292fsTer9), necessitating close monitoring of the socket during follow-up visits. Three months after the operation, fundus examination revealed yellow-white lesions in the left eye, and bilateral retinoblastoma was diagnosed (Group E in the right eye, Group C in the left eye). Based on the ICRB and pTNM stages, the patient underwent six rounds of systemic intravenous chemotherapy and three rounds of cryotherapy in the left eye. No recurrence was detected with a 4-year follow-up. The patient was initially diagnosed with unilateral retinoblastoma, but later developed the disease in the contralateral eye during treatment, which was a case of metachronous bilateral retinoblastoma.

患者为 2 岁男性。家人发现孩子右眼瞳孔区出现白色反光已有 6 天,于是带孩子来到上海市第九人民医院眼科就诊。经过全面的眼部和全身检查,患者被诊断为右眼视网膜母细胞瘤(E组,cT2bN0M0)。右眼被切除,病理分期为 pT3cN0M0。术后,采用 VEC 方案进行了全身静脉化疗。基因检测发现 RB1 基因有一个种系突变:c.874 (exon9) delT (p.Tyr292fsTer9),因此需要在随访期间对眼窝进行密切监测。术后三个月,眼底检查发现左眼有黄白色病变,确诊为双侧视网膜母细胞瘤(右眼为 E 组,左眼为 C 组)。根据 ICRB 和 pTNM 分期,患者接受了六轮全身静脉化疗和三轮左眼冷冻治疗。4 年随访未发现复发。患者最初被诊断为单侧视网膜母细胞瘤,但后来在治疗过程中对侧眼睛也出现了这种疾病,这是一例前后相继的双侧视网膜母细胞瘤。
{"title":"[Metachronous bilateral retinoblastoma: a case report].","authors":"Reyizha Mengjiang, J Yang, X Y Wen, J Y Fan","doi":"10.3760/cma.j.issn.cn112142-20240129-00053","DOIUrl":"10.3760/cma.j.issn.cn112142-20240129-00053","url":null,"abstract":"<p><p>The patient is a 2-year-old male. The family consulted the Department of Ophthalmology, Shanghai Ninth People's Hospital, after noticing a white reflection in the pupil area of the child's right eye for 6 days. Following a thorough ocular and systemic examination, the patient was diagnosed with retinoblastoma (Group E, cT2bN0M0) of the right eye. The right eye was enucleated and classified as pathological stage pT3cN0M0. Postoperatively, systemic intravenous chemotherapy with the VEC regimen was administered. Genetic testing revealed a germline mutation in the RB1 gene: c.874 (exon9) delT (p.Tyr292fsTer9), necessitating close monitoring of the socket during follow-up visits. Three months after the operation, fundus examination revealed yellow-white lesions in the left eye, and bilateral retinoblastoma was diagnosed (Group E in the right eye, Group C in the left eye). Based on the ICRB and pTNM stages, the patient underwent six rounds of systemic intravenous chemotherapy and three rounds of cryotherapy in the left eye. No recurrence was detected with a 4-year follow-up. The patient was initially diagnosed with unilateral retinoblastoma, but later developed the disease in the contralateral eye during treatment, which was a case of metachronous bilateral retinoblastoma.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"776-778"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical and genetic characterization of three families with Nance-Horan syndrome caused by NHS gene mutations]. [由 NHS 基因突变引起的三个 Nance-Horan 综合征家族的临床和遗传特征]。
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.cn112142-20231113-00230
L Li, G Y Zheng, J X Song, J F Yue, N Tan

Objective: To explore the clinical phenotypes and pathogenic gene variation characteristics of three Chinese Han ethnic families affected by Nance-Horan syndrome, a rare X-linked genetic disorder. Methods: A pedigree investigation study was conducted at the First Affiliated Hospital of Zhengzhou University, collecting clinical data from three Chinese Han families with Nance-Horan syndrome between February 2009 and September 2018. Detailed family histories, comprehensive ophthalmological and systemic examinations were documented. Pedigree charts were created, and genetic inheritance patterns were analyzed to preliminarily diagnose the probands and other affected individuals. Genomic DNA was extracted from peripheral blood samples of family members, and next-generation sequencing was used to screen for target gene variations, which were confirmed by Sanger sequencing. Pathogenicity of the genetic variants and their impact on three-dimensional protein structure were analyzed using MutationTaster and computer-aided protein modeling. Results: In Family 1, there are 5 patients, including 4 females (aged 42, 37, 9 and 7) and 1 males (aged 12). In Family 2, there are 5 patients, including 3 females (aged 54, 32 and 16) and 2 males (aged 26 and 9). In Family 3, there are 8 patients, including 5 females (aged 69, 42, 37, 35 and 14) and 3 males (aged 10, 7 and 4). All probands in the three families exhibited nuclear cataracts with typical congenital hereditary cataract features, but no noticeable abnormalities in facial appearance or teeth. Next-generation sequencing identified new variation sites in the NHS gene, specifically c.2519_2520del, exon3del, and c.3847C>T. These variations included nonsense mutation p.(Ser840*), exon deletion p.(?), and nonsense mutation p.(Gln1283*). Combined clinical and genetic sequencing results confirmed X-linked Nance-Horan syndrome in all three families. Bioinformatics analysis indicated these variation sites were pathogenic and resulted in abnormal three-dimensional protein structures, likely being the main cause of Nance-Horan syndrome. Conclusion: The majority of patients from the three Nance-Horan syndrome families studied were affected by congenital hereditary cataracts characterized by nuclear opacities.The NHS gene variations c.2519_2520del, exon3del, and c.3847C>T are newly identified pathogenic sites in Nance-Horan syndrome, reported for the first time across three different families.

研究目的探讨三个中国汉族南斯-贺兰综合征(一种罕见的 X 连锁遗传病)家族的临床表型和致病基因变异特征。方法在郑州大学第一附属医院进行了一项血统调查研究,收集了2009年2月至2018年9月期间三个中国汉族南斯-贺兰综合征家族的临床资料。详细记录了家族病史、全面的眼科和全身检查。绘制了家系图,并分析了遗传模式,以初步诊断探查者和其他受影响的个体。从家庭成员的外周血样本中提取基因组 DNA,并使用新一代测序技术筛选目标基因变异,这些变异通过桑格测序技术得到确认。利用 MutationTaster 和计算机辅助蛋白质建模分析了基因变异的致病性及其对三维蛋白质结构的影响。结果:家族 1 共有 5 名患者,包括 4 名女性(42 岁、37 岁、9 岁和 7 岁)和 1 名男性(12 岁)。家族 2 有 5 名患者,包括 3 名女性(年龄分别为 54、32 和 16 岁)和 2 名男性(年龄分别为 26 和 9 岁)。家族 3 共有 8 名患者,包括 5 名女性(69、42、37、35 和 14 岁)和 3 名男性(10、7 和 4 岁)。这三个家族的所有原发性患者都患有核性白内障,具有典型的先天性遗传性白内障特征,但面部外观或牙齿没有明显异常。下一代测序发现了 NHS 基因的新变异位点,特别是 c.2519_2520del、exon3del 和 c.3847C>T。这些变异包括无义突变 p.(Ser840*)、外显子缺失 p.(?)和无义突变 p.(Gln1283*)。综合临床和基因测序结果证实,这三个家庭中均存在 X 连锁南希-贺兰综合征。生物信息学分析表明,这些变异位点具有致病性,会导致蛋白质三维结构异常,可能是导致南斯-霍兰综合征的主要原因。结论NHS基因变异c.2519_2520del、exon3del和c.3847C>T是南希-贺兰综合征新发现的致病位点,首次在三个不同的家族中报道。
{"title":"[Clinical and genetic characterization of three families with Nance-Horan syndrome caused by NHS gene mutations].","authors":"L Li, G Y Zheng, J X Song, J F Yue, N Tan","doi":"10.3760/cma.j.cn112142-20231113-00230","DOIUrl":"10.3760/cma.j.cn112142-20231113-00230","url":null,"abstract":"<p><p><b>Objective:</b> To explore the clinical phenotypes and pathogenic gene variation characteristics of three Chinese Han ethnic families affected by Nance-Horan syndrome, a rare X-linked genetic disorder. <b>Methods:</b> A pedigree investigation study was conducted at the First Affiliated Hospital of Zhengzhou University, collecting clinical data from three Chinese Han families with Nance-Horan syndrome between February 2009 and September 2018. Detailed family histories, comprehensive ophthalmological and systemic examinations were documented. Pedigree charts were created, and genetic inheritance patterns were analyzed to preliminarily diagnose the probands and other affected individuals. Genomic DNA was extracted from peripheral blood samples of family members, and next-generation sequencing was used to screen for target gene variations, which were confirmed by Sanger sequencing. Pathogenicity of the genetic variants and their impact on three-dimensional protein structure were analyzed using MutationTaster and computer-aided protein modeling. <b>Results:</b> In Family 1, there are 5 patients, including 4 females (aged 42, 37, 9 and 7) and 1 males (aged 12). In Family 2, there are 5 patients, including 3 females (aged 54, 32 and 16) and 2 males (aged 26 and 9). In Family 3, there are 8 patients, including 5 females (aged 69, 42, 37, 35 and 14) and 3 males (aged 10, 7 and 4). All probands in the three families exhibited nuclear cataracts with typical congenital hereditary cataract features, but no noticeable abnormalities in facial appearance or teeth. Next-generation sequencing identified new variation sites in the NHS gene, specifically c.2519_2520del, exon3del, and c.3847C>T. These variations included nonsense mutation p.(Ser840*), exon deletion p.(?), and nonsense mutation p.(Gln1283*). Combined clinical and genetic sequencing results confirmed X-linked Nance-Horan syndrome in all three families. Bioinformatics analysis indicated these variation sites were pathogenic and resulted in abnormal three-dimensional protein structures, likely being the main cause of Nance-Horan syndrome. <b>Conclusion:</b> The majority of patients from the three Nance-Horan syndrome families studied were affected by congenital hereditary cataracts characterized by nuclear opacities.The NHS gene variations c.2519_2520del, exon3del, and c.3847C>T are newly identified pathogenic sites in Nance-Horan syndrome, reported for the first time across three different families.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"757-765"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Visual rehabilitation treatment for a patient with hemifield slide after pituitary adenoma resection: a case report]. [垂体腺瘤切除术后半影滑动患者的视觉康复治疗:病例报告]。
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.issn.cn112142-20240410-00162
X Q Wang, R Song, J Ma, X P Liu

The patient is a 28-year-old male who presented with hemifield slide for 10 months following surgery for a large pituitary adenoma. A comprehensive ophthalmological examination and visual function tests were conducted, including best corrected visual acuity, visual field, stereopsis, accommodative convergence, Worth four-dot test, and prism cover test for quantifying strabismus, along with assessments using a depression scale and a visual function questionnaire. Rehabilitation plans included applying press-on prisms to correct vertical strabismus, binocular vision training, and saccadic training. After rehabilitation, the patient was able to maintain binocular single vision at near and intermediate distances, experienced improved visual comfort, and showed significant improvements in scores on the depression scale and visual function questionnaire.

患者是一名 28 岁的男性,因患巨大垂体腺瘤接受手术治疗,术后 10 个月出现半视野滑动。医生为患者进行了全面的眼科检查和视觉功能测试,包括最佳矫正视力、视野、立体视、容纳辐辏、沃斯四点测试和用于量化斜视的棱镜遮盖测试,并使用抑郁量表和视觉功能问卷进行了评估。康复计划包括使用加压棱镜矫正垂直斜视、双眼视觉训练和回视训练。康复后,患者能够在近距离和中距离保持双眼单视,视觉舒适度得到改善,抑郁量表和视觉功能问卷的得分也有显著提高。
{"title":"[Visual rehabilitation treatment for a patient with hemifield slide after pituitary adenoma resection: a case report].","authors":"X Q Wang, R Song, J Ma, X P Liu","doi":"10.3760/cma.j.issn.cn112142-20240410-00162","DOIUrl":"10.3760/cma.j.issn.cn112142-20240410-00162","url":null,"abstract":"<p><p>The patient is a 28-year-old male who presented with hemifield slide for 10 months following surgery for a large pituitary adenoma. A comprehensive ophthalmological examination and visual function tests were conducted, including best corrected visual acuity, visual field, stereopsis, accommodative convergence, Worth four-dot test, and prism cover test for quantifying strabismus, along with assessments using a depression scale and a visual function questionnaire. Rehabilitation plans included applying press-on prisms to correct vertical strabismus, binocular vision training, and saccadic training. After rehabilitation, the patient was able to maintain binocular single vision at near and intermediate distances, experienced improved visual comfort, and showed significant improvements in scores on the depression scale and visual function questionnaire.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"773-775"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical effect of XEN gel stent implantation or combined with phacoemusification and intraocular lens implantation on glaucoma]. [XEN凝胶支架植入术或联合超声乳化术和眼内晶体植入术对青光眼的临床疗效]。
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.cn112142-20231223-00304
B Zhang, X L Shen, X P Wang, D Gong, J H Guo, J T Wang
<p><p><b>Objective:</b> To evaluate the efficacy and safety of internal XEN gel stent implantation or combined with phacoemusification and intraocular lens (IOL) implantation in the treatment of glaucoma. <b>Methods:</b> It was a retrospective case series study. Forty-five patients (28 males and 17 females; 52 eyes) who had different types of glaucoma treated at the Shenzhen Eye Hospital from December 2021 to June 2023 were included. XEN gel stent implantation (the XEN group) or XEN implantation combined with phacoemusification and IOL implantation (the combined group) were performed in these patients. The postoperative follow-up was 18 months. The observational indexes included the best corrected visual acuity (recorded as the logarithm of the minimum angle of resolution), intraocular pressure (IOP), XEN implantation quadrant, number of IOP-lowering medications, corneal endothelial cell count, operation success rate and surgical complications. The one-way repeated measures of variance, LSD-<i>t</i> test, and rank sum test were used for statistical analysis. <b>Results:</b> There were 28 patients (33 eyes) in the XEN group and 17 patients (19 eyes) in the combined group. The postoperative best corrected visual acuity had no significant change in the XEN group, but improved significantly (0.21±0.30 at 6 months; <i>P</i><0.05) in the combined group, compared with the preoperative value. The IOP of the two groups at 18 months after surgery [(12.2±3.1) and (11.9±3.9) mmHg (1 mmHg=0.133 kPa)] was significantly lower than that before surgery [(22.1±8.5) and (19.4±10.2) mmHg; <i>P</i><0.05]. The average number of IOP-lowering medications in all patients was 3 (2, 3) before surgery and 0 (0, 0) at 18 months after surgery. The difference was statistically significant (<i>P</i><0.05). In the XEN group, the corneal endothelial cell count was (2 387.37±478.22) cells/mm² preoperatively and (2 193.89±311.96) cells/mm² at 12 months. The decrease showed no statistical significance. The XEN gel stent was implanted in the supranasal quadrant in 8 eyes (15.4%), in the inferonasal quadrant in 36 eyes (69.2%), and in the infratemporal quadrant in 8 eyes (15.4%). The operation success rate [complete success rate, 86.5% (45/52); conditional success rate, 9.6% (5/52)] was 96.2% (50/52). The filtering bleb scarring occurred in 9.6% (5/52) of eyes. A small amount of hyphema, postoperative shallow anterior chamber, transient hypertension, and intraoperative drain breakage were found in 7.7% (4/52) of eyes, respectively. A small amount of subconjunctival bleeding was observed in 5.8%(3/52) of eyes. Re-implantation of an XEN gel stent was performed in 5.8% (3/52) of eyes. The intraoperative conjunctival tissue rupture, hypotony macular edema, and drain exposure were observed in 1.9% (1/52) of eyes, respectively. <b>Conclusion:</b> The XEN gel stent implantation or combined with phacoemusification and IOL implantation was effective and safe in treating different types of glau
目的评估内 XEN 凝胶支架植入术或联合超声乳化术和人工晶体植入术治疗青光眼的有效性和安全性。研究方法这是一项回顾性病例系列研究。研究纳入了自2021年12月至2023年6月在深圳眼科医院接受治疗的45例不同类型青光眼患者(男28例,女17例;52眼)。这些患者均接受了XEN凝胶支架植入术(XEN组)或XEN植入术联合超声乳化术和人工晶体植入术(联合组)。术后随访 18 个月。观察指标包括最佳矫正视力(以最小分辨角的对数记录)、眼压(IOP)、XEN植入象限、降眼压药物次数、角膜内皮细胞计数、手术成功率和手术并发症。统计分析采用单因素重复方差分析、LSD-t 检验和秩和检验。结果XEN 组有 28 名患者(33 只眼),联合组有 17 名患者(19 只眼)。XEN 组的术后最佳矫正视力无明显变化,但在 6 个月时有明显改善(0.21±0.30;PPPC 结论:XEN 凝胶支架植入术是一种有效的治疗方法:XEN凝胶支架植入术或联合超声乳化术和人工晶体植入术治疗不同类型的青光眼有效且安全,但其长期临床疗效还需要多中心、大规模研究的进一步跟踪观察。
{"title":"[Clinical effect of XEN gel stent implantation or combined with phacoemusification and intraocular lens implantation on glaucoma].","authors":"B Zhang, X L Shen, X P Wang, D Gong, J H Guo, J T Wang","doi":"10.3760/cma.j.cn112142-20231223-00304","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20231223-00304","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the efficacy and safety of internal XEN gel stent implantation or combined with phacoemusification and intraocular lens (IOL) implantation in the treatment of glaucoma. &lt;b&gt;Methods:&lt;/b&gt; It was a retrospective case series study. Forty-five patients (28 males and 17 females; 52 eyes) who had different types of glaucoma treated at the Shenzhen Eye Hospital from December 2021 to June 2023 were included. XEN gel stent implantation (the XEN group) or XEN implantation combined with phacoemusification and IOL implantation (the combined group) were performed in these patients. The postoperative follow-up was 18 months. The observational indexes included the best corrected visual acuity (recorded as the logarithm of the minimum angle of resolution), intraocular pressure (IOP), XEN implantation quadrant, number of IOP-lowering medications, corneal endothelial cell count, operation success rate and surgical complications. The one-way repeated measures of variance, LSD-&lt;i&gt;t&lt;/i&gt; test, and rank sum test were used for statistical analysis. &lt;b&gt;Results:&lt;/b&gt; There were 28 patients (33 eyes) in the XEN group and 17 patients (19 eyes) in the combined group. The postoperative best corrected visual acuity had no significant change in the XEN group, but improved significantly (0.21±0.30 at 6 months; &lt;i&gt;P&lt;/i&gt;&lt;0.05) in the combined group, compared with the preoperative value. The IOP of the two groups at 18 months after surgery [(12.2±3.1) and (11.9±3.9) mmHg (1 mmHg=0.133 kPa)] was significantly lower than that before surgery [(22.1±8.5) and (19.4±10.2) mmHg; &lt;i&gt;P&lt;/i&gt;&lt;0.05]. The average number of IOP-lowering medications in all patients was 3 (2, 3) before surgery and 0 (0, 0) at 18 months after surgery. The difference was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). In the XEN group, the corneal endothelial cell count was (2 387.37±478.22) cells/mm² preoperatively and (2 193.89±311.96) cells/mm² at 12 months. The decrease showed no statistical significance. The XEN gel stent was implanted in the supranasal quadrant in 8 eyes (15.4%), in the inferonasal quadrant in 36 eyes (69.2%), and in the infratemporal quadrant in 8 eyes (15.4%). The operation success rate [complete success rate, 86.5% (45/52); conditional success rate, 9.6% (5/52)] was 96.2% (50/52). The filtering bleb scarring occurred in 9.6% (5/52) of eyes. A small amount of hyphema, postoperative shallow anterior chamber, transient hypertension, and intraoperative drain breakage were found in 7.7% (4/52) of eyes, respectively. A small amount of subconjunctival bleeding was observed in 5.8%(3/52) of eyes. Re-implantation of an XEN gel stent was performed in 5.8% (3/52) of eyes. The intraoperative conjunctival tissue rupture, hypotony macular edema, and drain exposure were observed in 1.9% (1/52) of eyes, respectively. &lt;b&gt;Conclusion:&lt;/b&gt; The XEN gel stent implantation or combined with phacoemusification and IOL implantation was effective and safe in treating different types of glau","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"746-756"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized eyes]. [玻璃体内抗血管内皮生长因子药物在玻璃体切除眼内的药代动力学]。
Q3 Medicine Pub Date : 2024-09-11 DOI: 10.3760/cma.j.cn112142-20231018-00153
J Zhu, J Liu, R R Zhu

Neovascular retinal diseases pose a significant burden, often resulting in visual impairment. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs serves as the primary therapeutic approach. Nonetheless, certain patients necessitate continued anti-VEGF treatment post-vitrectomy or other ocular surgeries. Emerging evidence suggests that variations in surgical techniques and postoperative vitreous cavity management may induce distinct intraocular pharmacokinetics (PK) of anti-VEGF agents following vitrectomy, prompting potential adjustments in therapeutic strategies. This review offers a thorough examination of the pharmacokinetic determinants impacting anti-VEGF drugs and their intraocular dynamics post-vitrectomy.

新生血管性视网膜疾病造成了巨大的负担,往往导致视力受损。主要的治疗方法是在玻璃体内注射抗血管内皮生长因子(VEGF)药物。然而,某些患者在接受玻璃体切除术或其他眼科手术后仍需继续接受抗血管内皮生长因子治疗。新的证据表明,手术技术和术后玻璃体腔管理的不同可能会导致玻璃体切除术后抗血管内皮生长因子药物的眼内药代动力学(PK)不同,从而促使治疗策略的潜在调整。本综述全面探讨了影响抗血管内皮生长因子药物的药代动力学决定因素及其在玻璃体切除术后的眼内动力学。
{"title":"[Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized eyes].","authors":"J Zhu, J Liu, R R Zhu","doi":"10.3760/cma.j.cn112142-20231018-00153","DOIUrl":"10.3760/cma.j.cn112142-20231018-00153","url":null,"abstract":"<p><p>Neovascular retinal diseases pose a significant burden, often resulting in visual impairment. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs serves as the primary therapeutic approach. Nonetheless, certain patients necessitate continued anti-VEGF treatment post-vitrectomy or other ocular surgeries. Emerging evidence suggests that variations in surgical techniques and postoperative vitreous cavity management may induce distinct intraocular pharmacokinetics (PK) of anti-VEGF agents following vitrectomy, prompting potential adjustments in therapeutic strategies. This review offers a thorough examination of the pharmacokinetic determinants impacting anti-VEGF drugs and their intraocular dynamics post-vitrectomy.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 9","pages":"787-792"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华眼科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1